Month: December 2018
We are very excited to announce the first round of national speakers for ACCM2019. We have a fantastic line up and it is sure to be an amazing conference with stimulating talks from both the international and national speakers.
Early Bird Registration will open in early 2019 and we hope to see you all in Sydney in June.
- Agata Smogorzewska(Genome Maintenance) [Link]
- Agnel Sfeir(Telomere Biology) [Link]
- Gerry Hanna(Senior Clinical Oncologist) [Link]
- Karlene Cimprich(Genome stability and DNA replication) [Link]
- Nikki Verrills (Newcastle Uni)
- Helena Richardson (La Trobe)
- Gretchen Poortinga (Peter Mac)
- Sharad Kumar (Uni SA)
- Mustrafa Krasraw (USyd)
- Olga Martin (Peter Mac)
- Mark Cowley (CCI-UNSW)
- Tony Papenfuss (WEHI)
- Jorg Hierhorst (SVI)
- Vi Wickramshinge (Peter Mac)
- Paul Clarke (TRI-UQ)
- John Lock (UNSW)
- Chris Jolly (Centenary Institute)
+ Lots more to come
Hope to see you all there
The 2019 ACCM…
View original post 16 more words
I am very excited to announce our new review paper which is out now in Front Cell Dev Biol [Link]. This is also the first paper from Dr Kamila Marzec who recently joined the lab. Great work!
MASTL kinase is a master regulator of mitosis, essential for ensuring that mitotic substrate phosphorylation is correctly maintained. It achieves this through the phosphorylation of alpha-endosulfine and subsequent inhibition of the tumour suppressor PP2A-B55 phosphatase. In recent years MASTL has also emerged as a novel oncogenic kinase that is upregulated in a number of cancer types, correlating with chromosome instability and poor patient survival. While the chromosome instability is likely directly linked to MASTL’s control of mitotic phosphorylation, several new studies indicated that MASTL has additional effects outside of mitosis and beyond regulation of PP2A-B55. These include control of normal DNA replication timing, and regulation of AKT/mTOR and Wnt/β-catenin oncogenic kinase signalling. In this review, we will examine the phenotypes and mechanisms for how MASTL, ENSA and PP2A-B55 deregulation drives tumour progression and metastasis. Finally, we will explore the rationale for the future development of MASTL inhibitors as new cancer therapeutics.